Search research articles

Search research articles

Related Experiment Video

Updated: Aug 14, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Engineering CD20 CARs with a Twist.

Lukas Scheller¹, Michael Hudecek¹

¹Lehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.

Cancer Immunology Research

|January 12, 2023

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination.

Nature communications·2026

Same author

Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.

Leukemia·2026

Same author

Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy.

Blood cancer discovery·2026

Same author

Vitamin C Conditioning Generates Tumor-Targeting CAR T Cells with Superior Cytotoxicity and Fitness in a Posttransplant Lymphoproliferative Disorder Tumor Model.

Molecular cancer therapeutics·2025

Same author

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy.

HemaSphere·2025

Same author

Fine tuning towards the next generation of engineered T cells.

Nature biomedical engineering·2025

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Researchers developed improved chimeric antigen receptor (CAR) T-cell therapies targeting CD20 for B-cell lymphoma. These novel CAR designs show curative efficacy in preclinical models, advancing potential treatments.

Area of Science:

Immunology
Oncology
Biotechnology

Background:

CD20 is a key target in B-cell lymphomas.
Conventional chimeric antigen receptor (CAR) T-cell therapies targeting CD20 have faced efficacy challenges.
Improved CAR designs are needed for effective lymphoma treatment.

Purpose of the Study:

To develop novel CD20 CAR T-cell designs with enhanced anti-lymphoma efficacy.
To investigate rational CAR design principles informed by structural biology.
To provide improved CAR candidates for clinical development.

Main Methods:

Development of modified CD20 CAR constructs with minimal deviations from conventional designs.
Preclinical testing of novel CAR T-cells in lymphoma models.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Related Experiment Videos

Last Updated: Aug 14, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

Evaluation of CAR efficacy and structural biology insights.

Main Results:

Several improved CD20 CAR designs demonstrated curative efficacy in preclinical lymphoma models.
The novel CARs represent advancements over conventional approaches.
Insights into CAR structural biology informed the design process.

Conclusions:

Novel CD20 CAR designs offer promising curative potential for B-cell lymphomas.
These findings support rational CAR design strategies informed by structural biology.
The developed CARs are candidates for further clinical development.